A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

NCT02096341 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Subcutaneous administration of RRx-001 is no longer of interest.

Conditions

Malignant Solid Tumor
Lymphomas

Interventions

DRUG: RRx-001

Sponsor

EpicentRx, Inc.